Lucy Teece | Stats Enthusiast

@stateecetics.bsky.social

644 Followers 457 Following

Statistical Science | Associate Director | Early Oncology | AstraZeneca + Volunteer for Royal Statistical Society + Founder of Celebrating Diversity SIG

Purple flyer for 4th annual International Day of Women in Statistics & Data Science Conference, advertising the session "Through her data lens: Women and books that shift the view" on 14 October 2025 at 12:15-12:30 BST with speakers Edith Milanzi, Penny Reynolds, Chiatra Nagaraja, Lucy Teece, and Bonita Natamba.
Sarah wears a rainbow coloured daisy crochet granny square cardigan, I'm in a bright yellow full length dress showing off my purple and blue unicorn mascot
Weekly calendar for 1st to 5th September showing which RSS conference sessions I plan to attend, some are highlighted to show which I will be chairing / supporting / speaking at
Mw holding a yellow fluffy chick toy with yellow glasses up to my face
Me on a megaphone shouting at 540 park runners from a bench on a beautiful sunny morning
Email from Rushcliffe Parkrun tanking volunteers and reminding them that this weeks Run Director will be me (Lucy Teece)!
Selection of Easter treats including rabbit shaped chocolates, chick shaped gummy sweets, and a small pen with a rabbit topper
Sunset on the top of a hill with a tall white structure (known as White Nancy) and a smiling Lucy
Photo of me in and Alec holding up coat hooks that we made ourselves wearing yellow aprons
2.2 Elements of Phase I-II Designs One may consider a phase I-II design to be like a Labradoodle, which is ob-tained by cross-breeding a Labrador Retriever with a Poodle. Labradoodles enjoy the desirable quality of heterosis, or hybrid vigor, since they have greater genetic diversity and hence better overall health than either of their parents. Hybrid clinical trial designs, if carefully constructed, enjoy similar advantages over the simpler designs that motivated them. The analogy is not strict, how-ever, since both Labradors and Poodles both are fine canine breeds, whereas the most commonly used phase I or phase II clinical trial designs suffer from logical and ethical flaws, as we demonstrated in Chapter 1
Meme of Hot Fuzz "Greater Good"
Sandi at a podium presenting a picture of Ada Lovelace
Extract from trials book: These examples may be summarized by the following key points for settings where both Efficacy and Toxicity may be observed quickly enough to make adaptive decisions. 1. 3+3 algorithms do a poor job of choosing a MTD. 2. Conventional phase I sample sizes are far too small. 3. It often does not make sense to base dose-finding on Toxicity alone. 4. It does not make sense to design a phase II trial based on Efficacy alone, since safety is an important concern in any clinical trial and the trial must be stopped if excessive Toxicity is observed. 5. The inclusion of a rule based on Efficacy to stop for futility in phase I-II underscores the important point that, at the completion of a phase I-II trial, there is no reason to conduct a conventional phase II trial since it already has been done.
Snowy landscape with frozen lake and clear blue sky
Book cover for the "Textbook of Clinical Trials in Oncology"
Nails with red, gold sparkles, and white stickers including Santa's face and snowflakes
A Christmas tree decorated with blue and silver ribbons and warm white fairy lights
A pie charts of hair band colours, including pink, maroon, silver, fuchsia, yellow, orange, black, green, blue, and brown hair bands
Spread of cakes and chocolates on table, including carrot cake, brownies, lemon and blueberry cake, and boxes of choclates
4 Cadbury selection boxes, 2 jars of Nutella, and 2 Terry's chocolate oranges piled on a table
Ceramic snowman with a painted blue coat and hat
A photo of me posing to show off my new bright yellow blazer, worn over a forest green shirt dress